![]() This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 7% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is $0.35 on $283.06 million in revenues for the coming quarter and $1.68 on $1.31 billion in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. ![]() You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Horizon Therapeutics was mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Horizon Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Horizon Therapeutics shares have added about 3.3% since the beginning of the year versus the S&P 500's decline of -11.2%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. ![]() The company has topped consensus revenue estimates four times over the last four quarters. This compares to year-ago revenues of $280.37 million. ![]() Horizon Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $355.91 million for the quarter ended March 2020, surpassing the Zacks Consensus Estimate by 25.28%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. A quarter ago, it was expected that this drugmaker would post earnings of $0.43 per share when it actually produced earnings of $0.56, delivering a surprise of 30.23%. This quarterly report represents an earnings surprise of 91.30%. These figures are adjusted for non-recurring items. This compares to earnings of $0.30 per share a year ago. Horizon Therapeutics ( HZNP Quick Quote HZNP - Free Report) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.23 per share.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |